Detection of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) and microRNA (miRNA) using blood samples (liquid biopsy) instead of cancer tissue proved useful in detecting progression and predicting prognosis of patients with bladder cancer, according to data presented at the recent 15th Urological Association of Asia Congress (UAA 2017) held in Hong Kong.
Urology research in Asia has seen a slight decrease in the last 10 years, with heterogeneity in regulations and healthcare systems and the lack of research platforms hindering the implementation of region-wide clinical trials.
Complicated and uncomplicated urinary tract infections (UTIs) in adults and children should be managed by identifying and treating predisposing or underlying risk factors, with antimicrobial treatment, if needed, based on urine culture results and regional antibiotic resistance patterns, according to new guidelines of the Urological Association of Asia (UAA) and Asian Association of UTI and STD (AAUS).
Prostate biopsy using the multiparametric MRI/ultrasound fusion-guided (mpMRI/US) technique improves prostate cancer diagnosis and reduces the detection of clinically insignificant cancers, according to data presented the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
Infectious complications of prostate biopsy can be prevented by adopting the transperineal approach rather than the transrectal approach, and by pre-biopsy rectal disinfection and meticulous equipment preparation, according to data presented at the 15th Urological Association of Asia Congress held in Hong Kong.
Optimizing perioperative chemotherapy in bladder cancer (BC) presents a clinical challenge, as reflected in a debate at the 15th Urological Association of Asia Congress held in Hong Kong, which focused on the benefits and drawbacks of adjuvant chemotherapy (AC) after radical cystectomy (RC).
Practice-changing results from several clinical trials reported in the past 2 years have offered new effective treatment options for hormone-naïve prostate cancer (PC) patients, according to Dr Gerhardt Attard from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, who spoke at the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.
A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.